Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients With Advanced Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT06026410

Title field or adapter rule

{'original_value': 'Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients With Advanced Solid Tumors', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:23.483734+00:00

Published At

2026-10-14T00:00:00+00:00

Record Updated At

2026-10-14

Source Retrieved At

2026-10-31T22:17:52.415050+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Solid Tumors With HRAS Alterations", "Non Small Cell Lung Cancer (NSCLC)", "Colorectal Cancer (CRC)", "Pancreatic Ductal Adenocarcinoma (PDAC)", "Clear Cell Renal Cell Carcinoma (ccRCC)", "Renal Cell Carcinoma (Kidney Cancer)", "Non Clear Cell Renal Cell Carcinoma (nccRCC)"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-14", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT06026410"

protocolSection.identificationModule.officialTitle

"Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients With Advanced Solid Tumors"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["PHASE1"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Solid Tumors With HRAS Alterations (protocolSection.conditionsModule.conditions)
• Non Small Cell Lung Cancer (NSCLC) (protocolSection.conditionsModule.conditions)
• Colorectal Cancer (CRC) (protocolSection.conditionsModule.conditions)
• Pancreatic Ductal Adenocarcinoma (PDAC) (protocolSection.conditionsModule.conditions)
• Clear Cell Renal Cell Carcinoma (ccRCC) (protocolSection.conditionsModule.conditions)
• Renal Cell Carcinoma (Kidney Cancer) (protocolSection.conditionsModule.conditions)
• Non Clear Cell Renal Cell Carcinoma (nccRCC) (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Arm #1: RAS-altered advanced solid tumors, monotherapy (escalation phase)', 'Arm #2: Advanced or metastatic RCC, combination therapy (escalation phase)', 'Arm #3: Advanced or metastatic NSCLC, CRC, or PDAC, combination therapy (escalation phase)', 'Arm #4: Advanced or metastatic ccRCC, combination therapy (expansion phase)', 'Arm #6: Advanced or metastatic ccRCC, cabozantinib rollover to combination therapy (expansion phase)', 'Arm #7: Advanced or metastatic NSCLC, combination therapy (expansion phase)'], 'description': 'Oral administration', 'name': 'Darlifarnib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Arm #2: Advanced or metastatic RCC, combination therapy (escalation phase)', 'Arm #4: Advanced or metastatic ccRCC, combination therapy (expansion phase)', 'Arm #5: Advanced or metastatic ccRCC, monotherapy (expansion phase)', 'Arm #6: Advanced or metastatic ccRCC, cabozantinib rollover to combination therapy (expansion phase)'], 'description': 'Oral administration', 'name': 'Cabozantinib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
• {'armGroupLabels': ['Arm #3: Advanced or metastatic NSCLC, CRC, or PDAC, combination therapy (escalation phase)', 'Arm #7: Advanced or metastatic NSCLC, combination therapy (expansion phase)'], 'description': 'Oral administration', 'name': 'Adagrasib', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• Darlifarnib (protocolSection.armsInterventionsModule.interventions[].name)
• Cabozantinib (protocolSection.armsInterventionsModule.interventions[].name)
• Adagrasib (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.